Журнал рассеянного склероза

Краткий комментарий

Ups and Downs in MS Therapeutics

Abdul Aftab, and Pankaj Majlumdar

Краткий комментарий

Ups and Downs in MS Therapeutics

Abdul Aftab, and Pankaj Majlumdar

Краткий комментарий

Ups and Downs in MS Therapeutics

Abdul Aftab, and Pankaj Majlumdar

Краткий комментарий

Ups and Downs in MS Therapeutics

Abdul Aftab, and Pankaj Majlumdar

Краткий комментарий

Ups and Downs in MS Therapeutics

Abdul Aftab, and Pankaj Majlumdar

Перспектива

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Martin Baum, Richard Glenn

Перспектива

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Martin Baum, Richard Glenn

Мини обзор

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

David Reeds, Sarah Frowler

Мини обзор

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

David Reeds, Sarah Frowler

Перспектива

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Martin Baum, Richard Glenn

Перспектива

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Martin Baum, Richard Glenn

Мини обзор

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

David Reeds, Sarah Frowler

Перспектива

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Martin Baum, Richard Glenn

Мини обзор

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

David Reeds, Sarah Frowler

Мини обзор

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

David Reeds, Sarah Frowler

Перспектива

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Elche Greeds, Oman Godsy

Перспектива

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Elche Greeds, Oman Godsy

Перспектива

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Elche Greeds, Oman Godsy

Перспектива

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Elche Greeds, Oman Godsy

Перспектива

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Elche Greeds, Oman Godsy

исследовательская статья

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

Johnny Michael Sakr

исследовательская статья

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

Johnny Michael Sakr

исследовательская статья

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

Johnny Michael Sakr

исследовательская статья

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

Johnny Michael Sakr

Объем 11, Проблема 1 (2024)

Ups and Downs in MS Therapeutics

Ups and Downs in MS Therapeutics

Ups and Downs in MS Therapeutics

Ups and Downs in MS Therapeutics

Ups and Downs in MS Therapeutics

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

Основные моменты журнала

Индексировано в